US equities |
MU $904.90 ▲+2.97% NVDA $217.09 ▲+1.38% AMZN $262.45 ▲+4.98% TSLA $368.06 ▲+3.76% AAPL $342.94 ▼-0.15% SNDK $1,371.12 ▲+5.53% META $705.44 ▼-0.55% SPCX $147.96 ▲+1.32%
FinancialContent

Vogenx Inc - Common Stock (NQ:VOGX)

15.92 +1.39 (+9.57%)
Delayed Quote Updated: 4:00 PM EDT, Oct 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vogenx Inc - Common Stock

News headline image
Vogenx Initiates Phase 2b EMERGE Study of Mizagliflozin for Post-Bariatric Hypoglycemia
Randomized, double-blind, placebo-controlled trial will evaluate two doses of the first-in-class, minimally absorbed SGLT1 inhibitor in patients with recurrent hypoglycemia following bariatric surgery 
From Vogenx, Inc.
Via ACCESS Newswire
News headline image
Vogenx Appoints Board Member Richard Gorman as Chief Commercial Officer
Thirty-year biopharmaceutical commercial leader transitions from the Board of Directors to Chief Commercial Officer Appointment strengthens corporate strategy, business development and commercial... 
From Vogenx, Inc.
Via ACCESS Newswire
News headline image
Vogenx Appoints Ken Toombs to Board of Directors
Former Chief Executive Officer of PA Consulting brings three decades of global professional services and life sciences leadership experience Appointment broadens independent oversight as the Company... 
From Vogenx, Inc.
Via ACCESS Newswire
News headline image
Vogenx Announces Closing of Initial Public Offering
From Vogenx, Inc.
Via ACCESS Newswire